Why Individuals Respond To COVID-19 Differently: A Battle of Sexes?
Article Sidebar
-
SARS-CoV-2 (COVID-19), Infection, Genetic Variation, Bioinformatics
Abstract
Several factors including genetic variations, cytokine storm (CS), macrophage activated syndrome (MAS), and lymphopenia have been recently discovered to influence the severity of COVID-19. Many studies have exclusively studied the pathogenesis of this disease, which includes the entry of the virus into the body, multiplication and spread, the progression of tissue damage, and the production of an immune response. However, questions like what makes some people more vulnerable than others to SARS-CoV-2 - the causative agent of the coronavirus disease; the role of gene networks in determining or influencing the efficiency of infection or the severity of COVID-19 symptoms are still in the valley of obscurity. What makes some SARS-CoV-2 infected individuals extremely sensitive to the development of acute respiratory distress syndrome (ARDS) while others are asymptomatic remains to be understood. Herein, we review the impact of a genetic variant in susceptibility and severity among sex and gender disparities, the significance of this variation in cases of severity and immune responses. Furthermore, we address major characteristics in severe COVID-19 cases, such as biochemical and homeostatic effects. For example, lymphocyte count and concentrations of inflammatory mediators within patients. Also, this paper identifies key clinical indicators of severe infections in the presence of cytokine storm and lymphopenia. Moreover, it takes into account predisposing factors that induce the severity of symptoms and underline the differences between mild and severe infections. Lastly, we explained the benefits of using bioinformatics to accelerate the progress made in COVID-19 research and future perspective in this research area.
Full text article
References
2. Enard D, Cai L, Gwennap C, Petrov DA. (2016). Viruses are a dominant driver of protein adaptation in mammals. eLife 5:e12469.
3. Karlberg J, Chong DS, Lai WY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Am. J. Epidemiol. 2004;159:229â231.
4. Alghamdi IG, et al. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. Int. J. Gen. Med. 2014;7:417â423.
5. Meng Y, et al. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients. PLOS Pathog. 2020;16:e1008520.
6. Prokop JW, Deschepper CF. (2015). Chromosome Y genetic variants: Impact in animal models and on human disease. Physiol Genomics. 2015;47(11):525â537.
7. Arnold AP. (2009). The organizational-activational hypothesis as the foundation for a unified theory of sexual differentiation of all mammalian tissues. Horm Behav. 2009;55(5):570â578.
8. Bellott DW, et al. (2014). Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators. Nature. 2014;508(7497):494â499.
9. Dimitry N. Krementsov, Laure K. Case, Oliver Dienz, Abbas Raza, Qian Fang, Jennifer L. Ather, Matthew E. Poynter, Jonathan E. Boyson, Janice Y. Bunn, and Cory Teuscher. (2017). Genetic variation in chromosome Y regulates susceptibility to influenza A virus infection. Proc Natl Acad Sci U S A. 2017 Mar 28; 114(13): 3491â3496.
10. Fish EN. (2008). The X-files in immunity: sex-based differences predispose immune responses. Nat. Rev. Immunol. 2008;8:737â744.
11. Flanagan KL. (2014). Sexual dimorphism in biomedical research: a call to analyse by sex. Trans. R. Soc. Trop. Med. Hyg. 2014;108:385â387.
12. Schurz, H., Salie, M., Tromp, G. et al. The X chromosome and sex-specific effects in infectious disease susceptibility. Hum Genomics 13, 2 (2019). https://doi.org/10.1186/s40246-018-0185-z
13. Klein SL, Marriott I, Fish EN. (2015). Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109(1):9â15. doi: 10.1093/trstmh/tru167.
14. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. (2017). Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol (2017) 198(10):4046â53.10.4049/jimmunol.1601896
15. Sapana Kadel and Susan Kovats. (2018). Sex Hormones Regulate Innate Immune Cells and Promote Sex Differences in Respiratory Virus Infection. Front Immunol. 2018; 9: 1653. Published online 2018 Jul 20. doi: 10.3389/fimmu.2018.01653
16. Li MâY, Li L, Zhang Y, Wang XâS. (2020). Expression of the SARSâCoVâ2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020;9:45.
17. Walls AC, et al. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020. 10.1016/j.cell.2020.02.058.
18. Hoffmann M, et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020. 10.1016/j.cell.2020.02.052.
19. Austin Nguyen, Julianne K. David, Sean K. Maden, Mary A. Wood, Benjamin R. Weeder, Abhinav Nellore, and Reid F. Thompson. (2020). Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2. J Virol. 2020 Jul; 94(13): e00510-20. Published online 2020 Jun 16. Prepublished online 2020 Apr 17. doi: 10.1128/JVI.00510-20
20. Lin M, Tseng HK, Trejaut JA, et al. (2003). Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet. 2003;4:9.
21. Jose,R. and Manuel,A. (2020) âCOVID-19 cytokine storm: the interplay between inflammation and coagulationâ, The Lancet, 8(6), p.1-2. https://doi.org/10.1016/S2213-2600(20)30216-2
22. Soy,M. et al (2020) âCytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatmentâ, SpringerLink, p.1-10. https://doi.org/10.1007/s10067-020-05190-5
23. Zhao,Q. et al (2020) âLymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysisâ, International journal of infectious diseases, 96, p.131-135. https://doi.org/10.1016/j.ijid.2020.04.086
24. Tan,L. et al (2020) âLymphopenia predicts disease severity of COVID-19: a descriptive and predictive studyâ, Signal Transduction and Targeted Therapy volume, 33(5), p.1-3. https://doi.org/10.1038/s41392-020-0148-4
25. Junior,A. et al (2020) âA Balancing Act: MDA5 in Antiviral Immunity and Autoinflammationâ, Trends in Microbiology, 27(1), p.75-85. https://doi.org/10.1016/j.tim.2018.08.007
26. Huang,I. and Pranata,R. (2020) âLymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysisâ, Journal of intensive Care, 8(36), p.1-10. https://doi.org/10.11
86/s40560-020-00453-4
27. Koff,W. and Williams,M. (2020) âCovid-19 and Immunity in Aging Populations â A New Research Agendaâ, The New England Journal of Medicine, p.1-3. 10.1056/NEJMp2006761
28. Wen,W. et al (2020) âImmune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencingâ, Cell Discovery, 6(31), p.1-18. https://doi.org/10.1038/s41421-020-0168-9
29. Tufan,A. et al (2020) âCOVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugsâ, Turkish journal of medical Sciences, p.1-14. 10.3906/sag-2004-168
30. Takahashi,T. et al (2020) âSex differences in immune responses that underlie COVID-19 disease outcomesâ, Nature, p.1-26. https://doi.org/10.1038/s41586-020-2700-3 (2020)